Production (Stage)
Optimind Pharma Corp.
OMND
CNSX
| 02/28/2025 | 11/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 25.39% | -35.67% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 25.39% | -35.67% | |||
| Cost of Revenue | 15.19% | -20.20% | |||
| Gross Profit | 32.46% | -43.28% | |||
| SG&A Expenses | 85.37% | -78.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 63.22% | -72.12% | |||
| Operating Income | -212.24% | 91.37% | |||
| Income Before Tax | -183.33% | 89.05% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -183.33% | 89.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -183.33% | 89.05% | |||
| EBIT | -212.24% | 91.37% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -100.00% | 83.33% | |||
| Normalized Basic EPS | -- | 100.00% | |||
| EPS Diluted | -100.00% | 83.33% | |||
| Normalized Diluted EPS | -- | 100.00% | |||
| Average Basic Shares Outstanding | 0.10% | 0.52% | |||
| Average Diluted Shares Outstanding | 0.10% | 0.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||